Immunovant Share (IMVT)

Immunovant Inc. is a biopharmaceutical company focused on developing novel therapies for autoimmune diseases. The company's primary focus is on the development of fully human monoclonal antibodies that target the neonatal Fc receptor (FcRn). By inhibiting FcRn, Immunovant aims to reduce levels of disease-causing autoantibodies, potentially providing a new treatment approach for a range of autoimmune disorders. Immunovant's research and development efforts are centered on addressing unmet medical needs in areas such as myasthenia gravis, Graves' disease, warm autoimmune hemolytic anemia, and other antibody-mediated autoimmune conditions. The company operates within the biotechnology and pharmaceutical sectors, striving to improve the lives of patients affected by these debilitating diseases through innovative therapeutic solutions.